| 1. |
Safety of intravenous and subctaneous efgartigimod across multiple clinical trials in immunoglobulin G-mediated autoimmune disease （ポスター，一般） 2026/06/14
|
| 2. |
The role of complement in hematological disease: Spotlight on Cold Agglutinin Disease (CAD) （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2026/06/11
|
| 3. |
Intact COVID-19 vaccination response and overall safety in the phase 3, multicenter, double-blinded, placebo-controlled, randomized clnical trial of intravenous efgartigimod in ITP (ADVANCE IV) （口頭発表，一般） 2026/06/10
|
| 4. |
Phase 3 LUNA3 final efficacy and safety results for rilzabrutinib in the long term extension period in adults with persisten/chronic immune thrombocytopenia (ITP （口頭発表，一般） 2026/06/10
|
| 5. |
Ravulizumab in atypical hemolytic uremic syndrome: post hoc analysis of dialysis and end-stage kidney disease in two phase 3 trials （口頭発表，一般） 2026/06/02
|
| 6. |
Health-Related Quality of Life Outcomes for Marstacimab in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B With Inhibitors: Results From the Phase 3 BASIS Trial （口頭発表，一般） 2026/04/20
|
| 7. |
特発性肺線維症に対しニンテダニブ治療中に慢性骨髄性白血病を併発しチロシンキナーゼ阻害薬を併用した一例 （口頭発表，一般） 2025/11/22
|
| 8. |
Ravulizumab in atypical hemnolytic uremic syndrome: time to treatment analysis from a phase 3 trial （口頭発表，一般） 2025/11/08
|
| 9. |
後天性血栓性血小板減少性紫斑病を対象とした日本におけるカプラシズマブ製造販売後調査の中間解析 （口頭発表，一般） 2025/10/12
|
| 10. |
寒冷凝集素症に対するスチムリマブとリツキシマブの治療効果喪失後に診断されたB細胞性リンパ腫 （ポスター，一般） 2025/10/11
|
| 11. |
Rilzabrutinib improved quality of life in immune thrombocytopenia: Phase 3 Asian sub-group analysis （口頭発表，一般） 2025/10/10
|
| 12. |
Rilzabrutinib in immune thrombocytopenia (ITP): Asian/Japanese subgroup analysis of Phase 3 study （口頭発表，一般） 2025/10/10
|
| 13. |
Safety of intaravenous and subcutaneous efgartigimod reported from multiple global clinical trials in immunoglobulin G-mediated autoimmune disease （ポスター，一般） 2025/09/13
|
| 14. |
既治療の免疫性血小板減少症（ITP）患者におけるRilazbrutinib第III相試験の結果： LUNA3試験の全体集団およびアジア人集団の結果 （口頭発表，一般） 2025/06/29
|
| 15. |
血友病治療の新たな展開 （口頭発表） 2025/06/29
|
| 16. |
血友病遺伝子治療の共同意思決定とその支援 （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2025/06/29
|
| 17. |
特発性血小板減少性紫斑病の難治例に対するFcRn阻害薬エフガルチギモドの使用経験 （口頭発表，一般） 2025/06/28
|
| 18. |
ADVANCE NEXT: Phase 3 study of intravenous efgartigimod in primary immune thrombocytopenia （口頭発表，一般） 2025/06/23
|
| 19. |
Effect of Intravenous Efgartigimod on Immature Platelet Fraction inPrimary Immune Thrombocytopenia （口頭発表，一般） 2025/06/23
|
| 20. |
LUNA3 open-label period: First efficacy/safety with rilzabrutinib in previously treated ITP adults （口頭発表，一般） 2025/06/23
|
| 21. |
Platelet responses per IWG criteria for LUNA3 rilzabrutinib vs placebo in primary ITP patients （口頭発表，一般） 2025/06/22
|
| 22. |
Early initiation of TPO-RA reduces total corticosteroid dose in adult ITP: Japanese database analysis （ポスター，一般） 2025/06/21
|
| 23. |
Health-Related Quality of Life and Joint Health with Giroctocogene Fitelparvovec Gene Therapy （口頭発表，一般） 2025/06/20
|
| 24. |
エクリズマブから切替えたaHUS患者のラブリズマブ製造販売後調査の解析 （ポスター，一般） 2025/06/20
|
| 25. |
PHASE 3 LUNA3 STUDY: FIRST EFFICACY/SAFETY REPORT OF LONG-TERM EXTENSION PERIOD WITH RILZABRUTINIB IN ADULTS WITH PERSISTENT/CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) （口頭発表，一般） 2025/06/13
|
| 26. |
Effect of Efgartigimod IV on Immature Platelet Count Fraction in Primary Immune Thrombocytopenia （口頭発表，一般） 2025/06/12
|
| 27. |
Efgartigimod IV for the Treatment of Primary Immune Thrombocytopenia: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study With Open-Label Period (ADVANCE NEXT) （口頭発表，一般） 2025/06/12
|
| 28. |
CLINICAL FACTORS ASSOCIATED WITH RESPONSE TO RILZABRUTINIB, A BRUTON TYROSINE KINASE (BTK) INHIBITOR, IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP) TREATED IN THE PHASE 3 LUNA3 STUDY （口頭発表，一般） 2025/06/11
|
| 29. |
Ravulizumab in atypical haemolytic uraemic syndrome: analysis of quality of life outcomes in adult and pediatric phase 3 trials （ポスター，一般） 2025/06/04
|
| 30. |
Pospects for the ITP treatments based on long-term results of the FcRn inhibitor Efgartigimod （口頭発表） 2025/05/17
|
| 31. |
Efficacy and safety of ora bruton tyrosine kinase inhibitor (BTKi) rilzabrutinib in adults with previously treated immune thrombocytopenia (ITP): a phase 3, placebo controlled, parallel group, multi-center study (LUNA3) （口頭発表，一般） 2025/03/29
|
| 32. |
Bleed protection after giroctocogene fitelparvovec infusion in adults with moderately severe to severe hemophilia A in the phase 3 AFFINE trial. （ポスター，一般） 2025/02/04
|
| 33. |
Clinical management of factor VIII elevations above normal ranges post giroctocogene fitelparvovec in Phase 3 AFFINE study （口頭発表，一般） 2025/02/04
|
| 34. |
Efficacy and safety of oral bruton tyrosine kinase inhibitor (BTKi) rilzabrutinib in adults with previously treated immune thrombocytopenia (ITP): a phase 3, placebo-controlled, parallel-group, multicenter study (LUNA3) （口頭発表，一般） 2024/12/08
|
| 35. |
Improved health-related quality of life (HR-QOL) with oral bruton tyrosine kinase inhibitor (BTKi) rilzabrutinib vs placebo in adults with previoulsy treated immune thrombocytopenia (ITP): phase 3 LUNA3 multicenter study （ポスター，一般） 2024/12/08
|
| 36. |
Intravenous efgartigimod for the treatment of primary immune thrombocytopenia in adults: a planned, phase 3, randomised, double-blindded, placebo-controlled, parallel-arm study with open label period (ADVANCE NEXT) （口頭発表，一般） 2024/12/08
|
| 37. |
Safety and efficacy of efgartigmod in primary immune thrombocytopenia: ADVANCE IV+ 2 year analysis （口頭発表，一般） 2024/11/06
|
| 38. |
Ravulizumab in atypical hemolytic uremic syndrome: final analysis of efficacy and safety outcomes in two phase 3 trials. （口頭発表，一般） 2024/10/23
|
| 39. |
Baseline characteristics of Asian patients with persistent and chronic ITP enrolled in LUNA 3 trial （口頭発表，一般） 2024/10/12
|
| 40. |
Safety and efficacy of efgartigimod in primary immune thrombocytopenia: ADVANCE+ interim 2 year analysis （口頭発表，一般） 2024/10/12
|
| 41. |
BASIC CHARACTERISTICS OF ADULT PATIENTS WITH PREVIOUSLY TREATED IMMUNE THROMBOCYTOPENIA ENROLLED IN LUNA 3 PHASE 3 PLACEBO-CONTROLLED STUDY OF RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR （ポスター，一般） 2024/10/11
|
| 42. |
Post hoc analysis of ADAMTS13 activity and inhibitors in a phase 2/3 sutdy in Japanese patients with iTTP treated with caplacizumab （ポスター，一般） 2024/06/22
|
| 43. |
Time to platelet count response afetr IV efgartigimod in primary ITP （口頭発表，一般） 2024/06/15
|
| 44. |
Basic characteristics of adult patients with previously treated immune thrombocytopenia enrolled in LUNA3 phase 3 placebo-controlled study of rilzabrutinib, an oral bruton tyrosine kinase inhibitor （抄録提出，一般） 2024/06/13
|
| 45. |
Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease (CAD): 2 year follow up from the CARDINAL study （口頭発表，一般） 2023/06/09
|
| 46. |
Long term safety and efficacy of efgartigimod in patients with primary immune thrombocytopenia: interim results of the ADVANCE+ study （口頭発表，一般） 2023/06/08
|
| 47. |
Intravenous efgartigimod in adults with primary immune thrombocytopenia: results from the ADVANCE IV trial. （口頭発表，一般） 2023/04/25
|
| 48. |
SARS-Cov-2ワクチン接種後に発症した後天性血栓性血小板減少性紫斑病 （口頭発表，一般） 2023/03/11
|
| 49. |
後天性血友病A患者の出血リスクが高い経皮腎瘻造設術に対するエミシズマブとrFVIIaによる周術期管理 （口頭発表，一般） 2023/03/11
|
| 50. |
Efficacy and safety of intravenous Efgartigimod in adults with primary immune thrombocytopenia: results of ADVANCE IV, a Phase 3, multicentr, double-blinded, placebo-controlled, randomized clinical trial （口頭発表，一般） 2022/12/11
|
| 51. |
HELLP症候群との鑑別を要する妊娠関連TMA （口頭発表） 2022/10/29
|
| 52. |
Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome: Analysis of Two Phase 3 Studies （ポスター，一般） 2022/10/17
|
| 53. |
後天性血栓性血小板減少性紫斑病（TTP）診断と新規治療：抗VWF抗体カプラシズマブ （口頭発表） 2022/10/16
|
| 54. |
Efficacy and safety of caplacizumab for thrombotic thrombocytopenic purpura: Japanese Phase 2/3 study （口頭発表，一般） 2022/10/15
|
| 55. |
Phamacokinetic and pharmacodynamic simulations guide selection of the dose for administration of efgartigimod PH20 subcutaneously in a Phase 3 clinical trial in patients with primary immune thrombocytopenia （口頭発表，一般） 2022/09/26
|
| 56. |
Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease (CAD): a 2 year follow up from the CARDINAL study （口頭発表，一般） 2022/06/10
|
| 57. |
Inhibition of complement C1s with sutimlimab in patients with cold agglutinin diseasse (CAD): 2 year follow up from the CADRINAL study （口頭発表，一般） 2022/06/10
|
| 58. |
Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease, 2 year follow up from the CARDINAL study （ポスター，一般） 2022/06/09
|
| 59. |
Inhibition of complement C1s with sutimlimab in patients with cold aggulutinin disease , results following 9 week wash out period in phase 3 cardinal study. （ポスター，一般） 2022/06/09
|
| 60. |
Sutimlimab, a complement C1s inhibitor, provides sustained improvements in patient-reported outcomes in patients with cold agglutinin disease, 2 year follow up from the CARDINAL study （ポスター，一般） 2022/06/09
|
| 61. |
Eculizumab for adult patients with atypical haemolytic uremic syndrome: full dataset analysis of post-marketing surveillance in Japan （口頭発表，一般） 2022/05/20
|
| 62. |
La modélisation pharmacocinétique-pharmacodynamique supporte la sélection de la dose d'efgartigimod à administrer par voie sous-cutanée dans un essai clinique de phase 3 chez des patients atteints de purpura thrombopénique immunologique （ポスター，一般） 2021/12/16
|
| 63. |
Two year efficacy and safety of ravulizumab in adults and children with atypical HUS: analysis of two phase 3 studies. （口頭発表，一般） 2021/12/06
|
| 64. |
Phamakokinetic and pharmakodynamic simulations guide selection of the dose for administration of Efgartigimod PH20 subctutaneously in a phase 3 clinical trial in patients with primary immune thrombocytopenia （口頭発表，一般） 2021/12/05
|
|
5件表示
|
|
全件表示(64件)
|
